Glucagon-like peptide-1 receptor agonists(GLP-1RAs)and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus(T2DM).Both anti-diabetic treatments function by playing ...Glucagon-like peptide-1 receptor agonists(GLP-1RAs)and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus(T2DM).Both anti-diabetic treatments function by playing key modulatory roles in the incretin system.Though these drugs have been deemed effective in treating T2DM,the Food and Drug Administration(FDA)and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints.As a result,since 2008,the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety.The present review article strives to assess the safety and benefits of incretin-based therapy,a new class of antidiabetic drug,on the health of patient cardiovascular systems.In the process,this review will also provide a physiological overview of the incretin system and how key components function in T2DM.展开更多
目的研究探讨胰高血糖素样肽-1(GLP-1)受体激动剂对改善2型糖尿病(T2DM)伴代谢相关脂肪性肝病(MAFLD)患者糖脂水平及肝脏脂肪含量的影响,为后续的治疗总结临床经验。方法选取广州医科大学附属第四医院及广州中医药大学深圳医院(福田)201...目的研究探讨胰高血糖素样肽-1(GLP-1)受体激动剂对改善2型糖尿病(T2DM)伴代谢相关脂肪性肝病(MAFLD)患者糖脂水平及肝脏脂肪含量的影响,为后续的治疗总结临床经验。方法选取广州医科大学附属第四医院及广州中医药大学深圳医院(福田)2019年1月至2020年1月收治的90例T2DM伴MAFLD患者为研究对象,随机分为研究组(n=45)与对照组(n=45)。其中对照组患者服用盐酸二甲双胍片,研究组使用利拉鲁肽注射液,疗程90 d。观察比较两组患者的临床疗效、糖脂水平及肝脏脂肪含量变化。结果研究组及对照组治疗总有效率分别为93.33%、77.78%,研究组更高,差异有统计学意义(P<0.05);治疗前,两组患者的空腹血糖(FPG)、餐后2 h血糖(2 h PBG)以及糖化血红蛋白(HbA1C)比较,差异无统计学意义(P>0.05);治疗后,两组FPG、2 h PBG及HbA1C水平较治疗前均降低,研究组低于对照组,但差异无统计学意义(P>0.05);治疗前,两组患者的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)比较,差异无统计学意义(P>0.05);治疗后,两组TG、TC、LDL-C均显著降低,研究组的TG、TC、LDL-C低于对照组,差异有统计学意义(P<0.05);治疗后,两组HDL-C升高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗前,两组患者肝脏脂肪含量比较,差异无统计学意义(P>0.05);治疗后均降低,研究组的肝脏脂肪含量低于对照组,差异有统计学意义(P<0.05)。结论使用GLP-1受体激动剂可以有效改善T2DM伴MAFLD患者的糖脂水平及肝脏脂肪含量,有较好的临床应用价值。展开更多
基金supported by the National Natural Science Foundation of China(81974254,31870906,and 82170470)。
文摘Glucagon-like peptide-1 receptor agonists(GLP-1RAs)and dipeptidyl peptidase-4 inhibitors are commonly used treatments for patients with type 2 diabetes mellitus(T2DM).Both anti-diabetic treatments function by playing key modulatory roles in the incretin system.Though these drugs have been deemed effective in treating T2DM,the Food and Drug Administration(FDA)and some members of the scientific community have questioned the safety of these therapeutics relative to important cardiovascular endpoints.As a result,since 2008,the FDA has required all new drugs for glycemic control in T2DM patients to demonstrate cardiovascular safety.The present review article strives to assess the safety and benefits of incretin-based therapy,a new class of antidiabetic drug,on the health of patient cardiovascular systems.In the process,this review will also provide a physiological overview of the incretin system and how key components function in T2DM.
文摘目的研究探讨胰高血糖素样肽-1(GLP-1)受体激动剂对改善2型糖尿病(T2DM)伴代谢相关脂肪性肝病(MAFLD)患者糖脂水平及肝脏脂肪含量的影响,为后续的治疗总结临床经验。方法选取广州医科大学附属第四医院及广州中医药大学深圳医院(福田)2019年1月至2020年1月收治的90例T2DM伴MAFLD患者为研究对象,随机分为研究组(n=45)与对照组(n=45)。其中对照组患者服用盐酸二甲双胍片,研究组使用利拉鲁肽注射液,疗程90 d。观察比较两组患者的临床疗效、糖脂水平及肝脏脂肪含量变化。结果研究组及对照组治疗总有效率分别为93.33%、77.78%,研究组更高,差异有统计学意义(P<0.05);治疗前,两组患者的空腹血糖(FPG)、餐后2 h血糖(2 h PBG)以及糖化血红蛋白(HbA1C)比较,差异无统计学意义(P>0.05);治疗后,两组FPG、2 h PBG及HbA1C水平较治疗前均降低,研究组低于对照组,但差异无统计学意义(P>0.05);治疗前,两组患者的甘油三酯(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)比较,差异无统计学意义(P>0.05);治疗后,两组TG、TC、LDL-C均显著降低,研究组的TG、TC、LDL-C低于对照组,差异有统计学意义(P<0.05);治疗后,两组HDL-C升高,且研究组高于对照组,差异有统计学意义(P<0.05);治疗前,两组患者肝脏脂肪含量比较,差异无统计学意义(P>0.05);治疗后均降低,研究组的肝脏脂肪含量低于对照组,差异有统计学意义(P<0.05)。结论使用GLP-1受体激动剂可以有效改善T2DM伴MAFLD患者的糖脂水平及肝脏脂肪含量,有较好的临床应用价值。
